BioSpace News Archive

Drug Development

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy.

December 19, 2019
·
6 min read
Policy

UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

December 19, 2019
·
6 min read
Deals

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

December 19, 2019
·
1 min read
Deals

Lineage Cell Therapeutics Provides Shareholder Update

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, provided a year-end review and an outline of clinical and business plans for 2020.

December 19, 2019
·
10 min read
Business

Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda to Develop Novel Viral Immunotherapies

Turnstone and Takeda to co-develop and co-commercialize RIVAL-01, the lead candidate from Turnstone’s proprietary vaccinia virus platform, with a 50:50 global profit share

December 19, 2019
·
4 min read
Business

Zebra Medical Vision Announces Agreement With DePuy Synthes to Deploy Cloud Based Artificial Intelligence Orthopaedic Surgical Planning Tools

Zebra Medical Vision, the deep learning medical imaging analytics company, announces a global co-development and commercialization agreement with DePuy Synthes* to bring Artificial Intelligence opportunities to orthopaedics, based on imaging data.

December 19, 2019
·
2 min read
Drug Development

Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, announced the completion of patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial.

December 19, 2019
·
8 min read
Genetown

AVROBIO Announces First Patient Dosed Using plato™ Platform

Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease

December 19, 2019
·
6 min read
Bio NC

AstraZeneca Selects IQVIA OCE to Help Further its Digital Focus

IQVIA™ announced that AstraZeneca has selected IQVIA Technologies’ Orchestrated Customer Engagement platform to further its digital agenda and establish its “Field of the Future.”

December 19, 2019
·
2 min read
Bio NC

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease

December 19, 2019
·
8 min read